KKR Genetic Disorder L.P. 13D and 13G filings for BridgeBio Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-09-17 6:41 pm Sale | 2024-09-13 | 13D | BridgeBio Pharma, Inc. BBIO | KKR Genetic Disorder L.P. | 25,260,971 13.400% | -5,800,000 (-18.67%) | Filing |
| 2021-02-17 5:28 pm Sale | 2020-02-11 | 13D | BridgeBio Pharma, Inc. BBIO | KKR Genetic Disorder L.P. | 31,060,971 20.900% | -3,450,000 (-10.00%) | Filing |
| 2020-10-06 4:45 pm Unchanged | 2020-10-05 | 13D | BridgeBio Pharma, Inc. BBIO | KKR Genetic Disorder L.P. | 34,510,971 28.200% | 0 (Unchanged) | Filing |
| 2020-06-01 5:09 pm Sale | 2020-05-28 | 13D | BridgeBio Pharma, Inc. BBIO | KKR Genetic Disorder L.P. | 34,510,971 28.400% | -2,389,690 (-6.48%) | Filing |